<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PERGOLIDE</span><br/>(per'go-lide)<br/><span class="topboxtradename">Permax<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">anti-parkinson agent</span><br/><b>Prototype: </b>Levodopa<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.05 mg, 0.25 mg, 1 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Potent dopamine receptor agonist at both D<sub>1</sub>- and D<sub>2</sub>-dopamine receptor sites. Parkinsonism involves an excess of acetylcholine and a deficiency of dopamine neurotransmitters
         in the basal ganglia. The reduced tonic stimulation of dopaminergic D<sub>2</sub> receptors located on intrastriatal cholinergic neurons is most likely the cause of parkinsonian symptoms.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Thought that stimulation of the D<sub>2</sub>-dopamine receptor alleviates the majority of parkinsonian symptoms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to levodopa/carbidopa for the treatment of Parkinson's disease.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Acromegaly, hyperprolactinemia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pergolide or other ergot derivatives; history of hallucinations, history of hypotension; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiac dysrhythmias, pregnancy (category B); pericarditis, pericardial effusion, valvular heart disease; retroperitoneal
         fibrosis. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinson's Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 0.05 mg daily for 2 d, then increase by 0.1 or 0.15 mg/d every 3 d for the next 12 d, then dose may be increased
               by 0.25 mg every third day until the desired therapeutic response is achieved; give in divided doses t.i.d. (max: 5 mg/d)<br/><br/><span class="indicationtitle">Acromegaly</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.11.5 mg once/d<br/><br/><span class="indicationtitle">Hyperprolactinemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.0250.6 mg once/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that dosage increases should occur no more than every 3 d with Parkinson's disease.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Confusion, anxiety, light-headedness, headache,</span> transient somnolence (may fall asleep without warning), hallucinations, nightmares. <span class="typehead">CV:</span> Ventricular arrhythmias, PVCs, edema, <span class="speceff-common">orthostatic hypotension.</span> <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting,</span> constipation. <span class="typehead">Body as a Whole:</span> Rhinitis, withdrawal symptoms (hallucinations, confusion, paranoid ideations, worsening of parkinsonian symptoms). <span class="typehead">Skin:</span> Rash. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Suppresses <span class="alt">prolactin</span> levels.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Addition of pergolide to <b>levodopa</b> therapy has produced an increased incidence of dyskinesias in patients with Parkinson's disease; <b>haloperidol,</b> <span class="classification">phenothiazines</span> can antagonize therapeutic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; extensive first-pass metabolism. <span class="typehead">Onset:</span> Prolactin levels decrease within 1530 min. <span class="typehead">Peak:</span> Prolactin nadir in 15 h. <span class="typehead">Duration:</span> 2224 h. <span class="typehead">Distribution:</span> 90% protein bound; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 55% excreted in urine within 48 h; 4050% excreted in feces. <span class="typehead">Half-Life:</span> 27 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for orthostatic hypotension and syncope when initiating therapy.</li>
<li>Assess neurologic status; concurrent levodopa and pergolide may increase incidence of dyskinesias. If this occurs, levodopa
            may need to be reduced.
         </li>
<li>Monitor patients with cardiac arrhythmias carefully, as drug may induce certain arrhythmias in persons at risk.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: May fall asleep without warning. 						</li>
<li>Learn ways to reduce risk of orthostatic hypertension. Make position changes slowly and in stages.</li>
<li>Understand all potential adverse effects including hallucinations.</li>
<li>Report worsening neurologic status to physician.</li>
<li>Do not discontinue drug abruptly.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>